DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactResults

Aarey Drugs & Pharmaceuticals Limited — Board Meeting Intimation

NSE 3 hrs ago·7 Aug 2026, 1:34 pm

Company NSE

Aarey Drugs & Pharmaceuticals has announced a board meeting scheduled for August 14, 2026. The primary agenda for this meeting is to review and approve the company's unaudited financial results for the quarter that ended in June 2026.

This announcement is a routine corporate update that signals the company is nearing the end of its reporting cycle. For investors, the key takeaway is that the company's financial performance for the second quarter of 2026 will soon be made public. This data is critical for evaluating the company's current operational health and growth trajectory.

Investors should watch for the release of these results to gauge the company's performance against market expectations. Any significant deviation from analyst forecasts could impact the stock's valuation in the short term.